Keiichi Okano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keiichi Okano has a total of 261 co-authors. Here are the top co-authors by number of shared publications:
Yasuyuki Suzuki
Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Miki, Kagawa 761‑0793, Japan
27 shared publicationsMinoru Oshima
Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Takamatsu, Japan
22 shared publicationsHisashi Usuki
Department of Gastroenterological Surgery, Kagawa University School of Medicine
17 shared publicationsHajime Maeta
14 shared publicationsTakashi Maeba
First Department of Surgery, Kagawa Medical University, Kagawa, Japan
14 shared publications- Hironobu Suto
Department of Gastroenterological Surgery, Faculty of Medicine Kagawa University Kagawa Japan
13 shared publications
Latest Publications
- Open Access
Neoadjuvant Systemic Therapy for Resectable Intrahepatic Cholangiocarcinoma: From Retrospective Studies to Randomized Evidence
Complete resection remains the only potentially curative treatment for localized intrahepatic cholangiocarcinoma (iCCA), yet postoperative recurrence is common, particularly in patients with high-risk disease. Neoadjuvant systemic therapy may permit earlier control of occult micrometastatic disease, optimize the delivery of systemic treatment, and provide an in vivo assessment of tumor biology prior to major hepatectomy. These potential benefits must be balanced against treatment-related toxicity, surgical delay, and the risk of disease progression precluding resection. Early evidence was primarily derived from retrospective studies, which yielded inconsistent survival outcomes and exhibited substantial vulnerability to confounding and treatment-selection bias. The single-arm NEO-GAP trial subsequently demonstrated the feasibility of administering neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel followed by surgical resection. More recently, the randomized phase II–III ZSAB-neoGOLP trial showed that neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and toripalimab followed by surgery prolonged median event-free survival compared with upfront surgery (median: 18.0 vs. 8.7 months) without substantially compromising surgical feasibility. However, the interim overall survival analysis was inconclusive, and the generalizability of these findings beyond selected, medically fit patients treated at Chinese centers remains uncertain. This narrative review critically appraises the evolving evidence, discusses patient selection and perioperative treatment, and identifies priorities for future research. Current evidence supports the selective consideration of neoadjuvant therapy in medically fit patients with technically resectable but oncologically high-risk iCCA, rather than its routine use in all resectable cases.
Open AccessNeoadjuvant Systemic Therapy for Resectable Intrahepatic Cholangiocarcinoma: From Retrospective Studies to Randomized Evidence
Complete resection remains the only potentially curative treatment for localized intrahepatic cholangiocarcinoma (iCCA), yet postoperative recurrence is common, particularly in patients with high-risk disease. Neoadjuvant systemic therapy may permit earlier control of occult micrometastatic disease, optimize the delivery of systemic treatment, and provide an in vivo assessment of tumor biology prior to major hepatectomy. These potential benefits must be balanced against treatment-related toxicity, surgical delay, and the risk of disease progression precluding resection. Early evidence was primarily derived from retrospective studies, which yielded inconsistent survival outcomes and exhibited substantial vulnerability to confounding and treatment-selection bias. The single-arm NEO-GAP trial subsequently demonstrated the feasibility of administering neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel followed by surgical resection. More recently, the randomized phase II–III ZSAB-neoGOLP trial showed that neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and toripalimab followed by surgery prolonged median event-free survival compared with upfront surgery (median: 18.0 vs. 8.7 months) without substantially compromising surgical feasibility. However, the interim overall survival analysis was inconclusive, and the generalizability of these findings beyond selected, medically fit patients treated at Chinese centers remains uncertain. This narrative review critically appraises the evolving evidence, discusses patient selection and perioperative treatment, and identifies priorities for future research. Current evidence supports the selective consideration of neoadjuvant therapy in medically fit patients with technically resectable but oncologically high-risk iCCA, rather than its routine use in all resectable cases.
- 30 August 2026
- Published by Wiley in Journal of Surgical Oncology
Prognostic Value of the Preoperative Tumor‐to‐Blood Pool Standardized Uptake Value Ratio Derived From FDG‐PET/CT in Distal Bile Duct and Ampullary Cancers
Purpose: This study investigated the prognostic value of the preoperative tumor‐to‐blood pool standardized uptake value ratio (TBR) on 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography (FDG‐PET/CT) in patients undergoing pancreatoduodenectomy (PD) for distal bile duct and ampullary cancers. Methods: We retrospectively reviewed 100 patients who underwent PD between January 2011 and December 2024. TBR was calculated as tumor SUVmax divided by the SUV of the descending aorta. The optimal cutoff for overall survival (OS) was determined using time‐dependent ROC curve analysis. Survival outcomes were evaluated using Kaplan–Meier and multivariable Cox regression analyses. Results: A TBR cutoff of 2.30 was identified. Patients with high TBR (≥ 2.30) had significantly higher preoperative bilirubin, C‐reactive protein, and CA19‐9 levels, more frequent lymph node metastasis, poorer differentiation, and longer operation time than those with low TBR. High TBR was associated with worse OS and recurrence‐free survival (RFS) (both p < 0.001). Multivariate Cox regression confirmed high TBR as an independent predictor of poor OS (Hazard Ratio: 2.88, p = 0.044). Conclusions: Preoperative TBR on FDG‐PET/CT was associated with adverse pathological features and inferior survival in patients undergoing PD for distal bile duct and ampullary cancers. These findings suggest that TBR may be useful as an adjunctive PET‐derived marker for preoperative risk stratification.
- 30 August 2026
- Published by Wiley in Journal of Surgical Oncology
Prognostic Value of the Preoperative Tumor‐to‐Blood Pool Standardized Uptake Value Ratio Derived From FDG‐PET/CT in Distal Bile Duct and Ampullary Cancers
Purpose: This study investigated the prognostic value of the preoperative tumor‐to‐blood pool standardized uptake value ratio (TBR) on 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography (FDG‐PET/CT) in patients undergoing pancreatoduodenectomy (PD) for distal bile duct and ampullary cancers. Methods: We retrospectively reviewed 100 patients who underwent PD between January 2011 and December 2024. TBR was calculated as tumor SUVmax divided by the SUV of the descending aorta. The optimal cutoff for overall survival (OS) was determined using time‐dependent ROC curve analysis. Survival outcomes were evaluated using Kaplan–Meier and multivariable Cox regression analyses. Results: A TBR cutoff of 2.30 was identified. Patients with high TBR (≥ 2.30) had significantly higher preoperative bilirubin, C‐reactive protein, and CA19‐9 levels, more frequent lymph node metastasis, poorer differentiation, and longer operation time than those with low TBR. High TBR was associated with worse OS and recurrence‐free survival (RFS) (both p < 0.001). Multivariate Cox regression confirmed high TBR as an independent predictor of poor OS (Hazard Ratio: 2.88, p = 0.044). Conclusions: Preoperative TBR on FDG‐PET/CT was associated with adverse pathological features and inferior survival in patients undergoing PD for distal bile duct and ampullary cancers. These findings suggest that TBR may be useful as an adjunctive PET‐derived marker for preoperative risk stratification.
- 3 April 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (8) , 1-9
Outcomes of Spiral Versus Conventional Double Pigtail Plastic Stents in Permanent Transpapillary Gallbladder Drainage for Acute Cholecystitis
Purpose Endoscopic gallbladder stenting is an important definitive treatment option for acute cholecystitis in high-risk patients who are poor surgical candidates. In this study, we aimed to compare the outcomes between a novel 5-Fr spiral-shaped plastic stent (IYO-stent) and conventional 7-Fr double-pigtail stent (C-stent) for permanent transpapillary gallbladder drainage. Methods This retrospective cohort study included 56 patients with acute cholecystitis who underwent permanent endoscopic gallbladder stenting at 2 Japanese centers between 2019 and 2023 (C-stent, n = 27; IYO-stent, n = 29). The primary endpoint was event-free survival (EFS), defined as the time to recurrent cholecystitis, procedure-related complications, stent dysfunction, complications requiring intervention, or death. The secondary endpoints were cholecystitis recurrence-free survival and technical success. Results The median EFS was 10.6 months (95% confidence interval [CI], 2.7– not available) in the C-stent group and was not reached in the IYO-stent group; the 24-month EFS rates were 41.6% (95% CI, 22.2–59.9) and 92.0% (95% CI: 71.1–98.0), respectively. The IYO-stent was associated with a lower risk of events compared to the C-stent (adjusted hazard ratio 0.17, 95% CI 0.05–0.55). Cholecystitis recurrence-free survival rates at 24 months were 58.2% with C-stents and 100% with IYO-stents. The technical success was 100% in both groups. Conclusions In high-risk patients undergoing permanent endoscopic transpapillary gallbladder drainage, the novel 5-Fr IYO-stent showed superior long-term efficacy over conventional 7-Fr double-pigtail stents, with markedly improved event-free survival and absence of cholecystitis recurrence during follow-up.
- 3 April 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (8) , 1-9
Outcomes of Spiral Versus Conventional Double Pigtail Plastic Stents in Permanent Transpapillary Gallbladder Drainage for Acute Cholecystitis
Purpose Endoscopic gallbladder stenting is an important definitive treatment option for acute cholecystitis in high-risk patients who are poor surgical candidates. In this study, we aimed to compare the outcomes between a novel 5-Fr spiral-shaped plastic stent (IYO-stent) and conventional 7-Fr double-pigtail stent (C-stent) for permanent transpapillary gallbladder drainage. Methods This retrospective cohort study included 56 patients with acute cholecystitis who underwent permanent endoscopic gallbladder stenting at 2 Japanese centers between 2019 and 2023 (C-stent, n = 27; IYO-stent, n = 29). The primary endpoint was event-free survival (EFS), defined as the time to recurrent cholecystitis, procedure-related complications, stent dysfunction, complications requiring intervention, or death. The secondary endpoints were cholecystitis recurrence-free survival and technical success. Results The median EFS was 10.6 months (95% confidence interval [CI], 2.7– not available) in the C-stent group and was not reached in the IYO-stent group; the 24-month EFS rates were 41.6% (95% CI, 22.2–59.9) and 92.0% (95% CI: 71.1–98.0), respectively. The IYO-stent was associated with a lower risk of events compared to the C-stent (adjusted hazard ratio 0.17, 95% CI 0.05–0.55). Cholecystitis recurrence-free survival rates at 24 months were 58.2% with C-stents and 100% with IYO-stents. The technical success was 100% in both groups. Conclusions In high-risk patients undergoing permanent endoscopic transpapillary gallbladder drainage, the novel 5-Fr IYO-stent showed superior long-term efficacy over conventional 7-Fr double-pigtail stents, with markedly improved event-free survival and absence of cholecystitis recurrence during follow-up.
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0181
A Case of Intraductal Tubulopapillary Neoplasm of the Pancreas Requiring Superior Mesenteric Vein–Portal Vein Axis Resection after Systemic Chemotherapy
INTRODUCTION: Intraductal tubulopapillary neoplasm (ITPN) is a rare intraductal pancreatic tumor, accounting for approximately 3% of all intraductal neoplasms. ITPN is characteristically paucimucinous and lacks low-grade (adenomatous) components. Since reported cases of ITPN remain limited, its prognosis, prognostic factors, and role of perioperative chemotherapy are not well defined.CASE PRESENTATION: A 64-year-old man presented with loss of appetite and abdominal pain in year X–1. Endoscopic US–guided fine-needle aspiration (EUS-FNA) was performed, and the findings showed atypical epithelial cells suspicious for adenocarcinoma. The lesion was radiologically assessed as borderline-resectable pancreatic head cancer with portal venous involvement. Curative-intent resection was attempted at the referring hospital; however, the tumor was judged intraoperatively to be locally unresectable because safe vascular dissection around the superior mesenteric vein (SMV) was difficult. Choledochojejunostomy, cholecystectomy, and gastrojejunostomy were performed for obstructive jaundice and duodenal stenosis. From October X–1, the patient received gemcitabine plus nab-paclitaxel, followed by tegafur/gimeracil/oteracil. The maximum tumor diameter decreased from 60 to 50 mm, and the imaging response to systemic chemotherapy was classified as stable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, without distant progression. In May X, the patient was referred to our department for consideration of surgical treatment. Repeat EUS-FNA strongly suggested ITPN. Subtotal stomach-preserving pancreatoduodenectomy with SMV–portal vein (PV) axis resection and reconstruction was performed using a right common femoral vein graft. Postoperative right deep femoral vein thrombosis was managed with anticoagulation. The patient was discharged on POD 16, and follow-up CT 1 year after surgery confirmed thrombus resolution. Histopathological examination confirmed invasive ITPN without lymph node metastasis or vascular invasion. The histological treatment effect was classified as grade 1a according to the Japanese classification of pancreatic carcinoma by the Japan Pancreas Society, eighth edition, and as grade I according to the Evans classification. Adjuvant chemotherapy was not administered. The patient remained disease-free 29 months after surgery.CONCLUSIONS: This case highlights the importance of multidisciplinary re-evaluation in pancreatic tumors initially managed as pancreatic ductal adenocarcinoma, particularly when an unusual histology such as ITPN is suspected.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0181
Open AccessA Case of Intraductal Tubulopapillary Neoplasm of the Pancreas Requiring Superior Mesenteric Vein–Portal Vein Axis Resection after Systemic Chemotherapy
INTRODUCTION: Intraductal tubulopapillary neoplasm (ITPN) is a rare intraductal pancreatic tumor, accounting for approximately 3% of all intraductal neoplasms. ITPN is characteristically paucimucinous and lacks low-grade (adenomatous) components. Since reported cases of ITPN remain limited, its prognosis, prognostic factors, and role of perioperative chemotherapy are not well defined.CASE PRESENTATION: A 64-year-old man presented with loss of appetite and abdominal pain in year X–1. Endoscopic US–guided fine-needle aspiration (EUS-FNA) was performed, and the findings showed atypical epithelial cells suspicious for adenocarcinoma. The lesion was radiologically assessed as borderline-resectable pancreatic head cancer with portal venous involvement. Curative-intent resection was attempted at the referring hospital; however, the tumor was judged intraoperatively to be locally unresectable because safe vascular dissection around the superior mesenteric vein (SMV) was difficult. Choledochojejunostomy, cholecystectomy, and gastrojejunostomy were performed for obstructive jaundice and duodenal stenosis. From October X–1, the patient received gemcitabine plus nab-paclitaxel, followed by tegafur/gimeracil/oteracil. The maximum tumor diameter decreased from 60 to 50 mm, and the imaging response to systemic chemotherapy was classified as stable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, without distant progression. In May X, the patient was referred to our department for consideration of surgical treatment. Repeat EUS-FNA strongly suggested ITPN. Subtotal stomach-preserving pancreatoduodenectomy with SMV–portal vein (PV) axis resection and reconstruction was performed using a right common femoral vein graft. Postoperative right deep femoral vein thrombosis was managed with anticoagulation. The patient was discharged on POD 16, and follow-up CT 1 year after surgery confirmed thrombus resolution. Histopathological examination confirmed invasive ITPN without lymph node metastasis or vascular invasion. The histological treatment effect was classified as grade 1a according to the Japanese classification of pancreatic carcinoma by the Japan Pancreas Society, eighth edition, and as grade I according to the Evans classification. Adjuvant chemotherapy was not administered. The patient remained disease-free 29 months after surgery.CONCLUSIONS: This case highlights the importance of multidisciplinary re-evaluation in pancreatic tumors initially managed as pancreatic ductal adenocarcinoma, particularly when an unusual histology such as ITPN is suspected.
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0779
Pancreaticobiliary Fistula Caused by Intraductal Papillary Mucinous Adenoma Requiring Pancreaticoduodenectomy
INTRODUCTION: Fistula formation from the intraductal papillary mucinous neoplasm (IPMN) into neighboring organs is rare. We describe a case of pancreaticobiliary fistula with obstructive jaundice caused by an intraductal papillary mucinous adenoma (IPMA).CASE PRESENTATION: An 81-year-old man who was incidentally diagnosed with IPMN 11 years previously based on follow-up CT performed after nephrectomy for renal cell carcinoma. Gradual dilation of the main pancreatic duct was observed over time, confirming the high-risk stigmata for which surgery was recommended; however, the patient declined and was managed under surveillance. At a routine diabetes clinic visit, blood tests revealed inflammatory markers and hepatobiliary enzymes. Contrast-enhanced CT revealed a pancreatic head IPMN in extensive contact with the common bile duct with partial communication. Endoscopic nasobiliary drainage (ENBD) was performed, but resolution of jaundice proved difficult due to obstruction by mucin; therefore, we performed a subtotal stomach-preserving pancreaticoduodenectomy (SSPPD). Severe inflammation was observed around the pancreas and bile ducts at the surgical site. The postoperative course was favorable, and the patient was discharged on the POD 16. The histopathological diagnosis was intestinal-type IPMA.CONCLUSIONS: Most reported IPMN-related organ fistulas result from direct invasion by IPMC. By contrast, IPMA-related fistulation is exceedingly rare. We present an intestinal-type IPMA complicated by pancreaticobiliary fistula in which mucin defeated ENBD, necessitating SSPPD, and the patient had an uneventful recovery. This case shows that fistulation can occur even without IPMC and that early surgery should be considered in IPMN patients with pancreatobiliary fistula.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0779
Open AccessPancreaticobiliary Fistula Caused by Intraductal Papillary Mucinous Adenoma Requiring Pancreaticoduodenectomy
INTRODUCTION: Fistula formation from the intraductal papillary mucinous neoplasm (IPMN) into neighboring organs is rare. We describe a case of pancreaticobiliary fistula with obstructive jaundice caused by an intraductal papillary mucinous adenoma (IPMA).CASE PRESENTATION: An 81-year-old man who was incidentally diagnosed with IPMN 11 years previously based on follow-up CT performed after nephrectomy for renal cell carcinoma. Gradual dilation of the main pancreatic duct was observed over time, confirming the high-risk stigmata for which surgery was recommended; however, the patient declined and was managed under surveillance. At a routine diabetes clinic visit, blood tests revealed inflammatory markers and hepatobiliary enzymes. Contrast-enhanced CT revealed a pancreatic head IPMN in extensive contact with the common bile duct with partial communication. Endoscopic nasobiliary drainage (ENBD) was performed, but resolution of jaundice proved difficult due to obstruction by mucin; therefore, we performed a subtotal stomach-preserving pancreaticoduodenectomy (SSPPD). Severe inflammation was observed around the pancreas and bile ducts at the surgical site. The postoperative course was favorable, and the patient was discharged on the POD 16. The histopathological diagnosis was intestinal-type IPMA.CONCLUSIONS: Most reported IPMN-related organ fistulas result from direct invasion by IPMC. By contrast, IPMA-related fistulation is exceedingly rare. We present an intestinal-type IPMA complicated by pancreaticobiliary fistula in which mucin defeated ENBD, necessitating SSPPD, and the patient had an uneventful recovery. This case shows that fistulation can occur even without IPMC and that early surgery should be considered in IPMN patients with pancreatobiliary fistula.
- Open Access
- 30 January 2025
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 29 (4) , 1-11
Intravenous D‑allose administration improves blood glucose control by maintaining insulin secretion in diabetic mice with transplanted islets
Although pancreatic islet transplantation outcomes have improved, further refinements are required to extend the insulin withdrawal period. The present study examined whether intravenous D‑allose administration improves insulin secretion when pancreatic islets are transplanted into type 1 diabetes model mice. Alterations in casual blood glucose levels, intraperitoneal glucose tolerance test (IPGGT) results, the number of apoptotic cells in the engrafted cells, and caspase 3, heme oxygenase 1 and nitric oxide synthase 2 (NOS2) expression in the engrafted cells were examined using the following groups of type 1 diabetic model mice with transplanted pancreatic islets: Mice that received an intravenous injection of D‑allose (D‑group) and those that received physiological saline as a control (C‑group). The mice in the D‑group had significantly lower casual blood sugar levels for a longer duration than those in the C‑group. Regarding IPGGT, mice treated with D‑allose exhibited smaller changes in blood glucose levels compared with untreated mice. Consequently, the incremental area under the curve of glucose in D‑allose‑treated mice was significantly lower than that in D‑allose‑untreated mice. No difference was observed in the number of engrafted cells between the groups. NOS2 mRNA expression in the engrafted cells of the D‑group tended to be higher than that in the C‑group. In conclusion, intravenous administration of D‑allose significantly improved hyperglycemia and maintained stable blood glucose levels in type 1 diabetic mice after islet transplantation. Since there was no difference in the number of engrafted cells or apoptotic cells with or without intravenous D‑allose administration, D‑allose was considered to be effective in maintaining the cellular function of insulin secretion.
- 30 January 2025
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 29 (4) , 1-11
Open AccessIntravenous D‑allose administration improves blood glucose control by maintaining insulin secretion in diabetic mice with transplanted islets
Although pancreatic islet transplantation outcomes have improved, further refinements are required to extend the insulin withdrawal period. The present study examined whether intravenous D‑allose administration improves insulin secretion when pancreatic islets are transplanted into type 1 diabetes model mice. Alterations in casual blood glucose levels, intraperitoneal glucose tolerance test (IPGGT) results, the number of apoptotic cells in the engrafted cells, and caspase 3, heme oxygenase 1 and nitric oxide synthase 2 (NOS2) expression in the engrafted cells were examined using the following groups of type 1 diabetic model mice with transplanted pancreatic islets: Mice that received an intravenous injection of D‑allose (D‑group) and those that received physiological saline as a control (C‑group). The mice in the D‑group had significantly lower casual blood sugar levels for a longer duration than those in the C‑group. Regarding IPGGT, mice treated with D‑allose exhibited smaller changes in blood glucose levels compared with untreated mice. Consequently, the incremental area under the curve of glucose in D‑allose‑treated mice was significantly lower than that in D‑allose‑untreated mice. No difference was observed in the number of engrafted cells between the groups. NOS2 mRNA expression in the engrafted cells of the D‑group tended to be higher than that in the C‑group. In conclusion, intravenous administration of D‑allose significantly improved hyperglycemia and maintained stable blood glucose levels in type 1 diabetic mice after islet transplantation. Since there was no difference in the number of engrafted cells or apoptotic cells with or without intravenous D‑allose administration, D‑allose was considered to be effective in maintaining the cellular function of insulin secretion.
- 13 August 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (7) , 1133-1140
Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emission tomography in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma who underwent curative pancreatic resection after neoadjuvant chemoradiotherapy
- 13 August 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (7) , 1133-1140
Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emission tomography in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma who underwent curative pancreatic resection after neoadjuvant chemoradiotherapy
- 10 March 2024
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 31 (6) , 404-414
Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by curative pancreatic resection: A retrospective study using prospectively collected data
Background: Despite a strong association between nutritional indices and disease prognosis, evidence regarding the evaluation of nutritional indices after preoperative treatment for pancreatic ductal adenocarcinoma (PDAC) is insufficient. We evaluated the clinical significance of the prognostic nutritional index (PNI) in patients with resectable (R‐) and borderline resectable (BR‐) PDAC who received neoadjuvant chemoradiotherapy (NACRT) followed by pancreatic resection.Methods: We assessed 153 patients with R‐ and BR‐PDAC who underwent NACRT followed by curative resection between 2009 and 2022. We evaluated the association between preoperative PNI after NACRT and short‐ and long‐term outcomes.Results: The median preoperative PNI value after NACRT was 42.1, and the optimal cutoff value from the time‐dependent receiver operating characteristic curve was 38.6. The low PNI group (PNI < 38.6, n = 44) exhibited significantly worse inflammatory parameters, surgical outcomes, and prognoses than the high PNI group (PNI ≥ 38.6, n = 109). Multivariate analysis identified preoperative PNI ≤ 38.6 (hazard ratio [HR]: 2.32, 95% confidence interval [CI]: 1.00–5.38, p = .049), blood loss ≥1642 mL (HR: 3.05, 95% CI: 1.65–5.64, p < .001), node positive pathology (HR: 2.10, 95% CI: 1.32–3.34, p = .002), and lack of postoperative adjuvant chemotherapy (HR: 3.55, 95% CI: 2.05–6.15, p < .001) as significant predictors of overall survival.Conclusions: For patients with R‐ and BR‐PDAC receiving preoperative treatment, it is imperative to closely monitor their nutritional status when determining the optimal surgical procedure timing.
- 10 March 2024
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 31 (6) , 404-414
Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by curative pancreatic resection: A retrospective study using prospectively collected data
Background: Despite a strong association between nutritional indices and disease prognosis, evidence regarding the evaluation of nutritional indices after preoperative treatment for pancreatic ductal adenocarcinoma (PDAC) is insufficient. We evaluated the clinical significance of the prognostic nutritional index (PNI) in patients with resectable (R‐) and borderline resectable (BR‐) PDAC who received neoadjuvant chemoradiotherapy (NACRT) followed by pancreatic resection.Methods: We assessed 153 patients with R‐ and BR‐PDAC who underwent NACRT followed by curative resection between 2009 and 2022. We evaluated the association between preoperative PNI after NACRT and short‐ and long‐term outcomes.Results: The median preoperative PNI value after NACRT was 42.1, and the optimal cutoff value from the time‐dependent receiver operating characteristic curve was 38.6. The low PNI group (PNI < 38.6, n = 44) exhibited significantly worse inflammatory parameters, surgical outcomes, and prognoses than the high PNI group (PNI ≥ 38.6, n = 109). Multivariate analysis identified preoperative PNI ≤ 38.6 (hazard ratio [HR]: 2.32, 95% confidence interval [CI]: 1.00–5.38, p = .049), blood loss ≥1642 mL (HR: 3.05, 95% CI: 1.65–5.64, p < .001), node positive pathology (HR: 2.10, 95% CI: 1.32–3.34, p = .002), and lack of postoperative adjuvant chemotherapy (HR: 3.55, 95% CI: 2.05–6.15, p < .001) as significant predictors of overall survival.Conclusions: For patients with R‐ and BR‐PDAC receiving preoperative treatment, it is imperative to closely monitor their nutritional status when determining the optimal surgical procedure timing.
- Open Access
- 21 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1216
Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable Pancreatic Cancer: A Retrospective Study
Background: The efficacy of neoadjuvant chemoradiotherapy (NACRT) followed by pancreatoduodenectomy (PD) in elderly patients with pancreatic ductal adenocarcinoma (PDAC) remains unclear. Methods: This retrospective analysis of prospectively collected data examined the effect of NACRT followed by PD in elderly patients with PDAC. A total of 112 patients with resectable (R-) and borderline resectable (BR-) PDAC, who were planned for PD and received NACRT between 2009 and 2022, were assessed. Changes induced by NACRT, surgical outcomes, nutritional status, renal and endocrine functions, and prognosis were compared between elderly (≥75 years, n = 43) and non-elderly (n = 69) patients over two years following PD. Results: Completion and adverse event rates during NACRT, nutritional status, renal function, endocrine function over two years postoperatively, and prognosis did not significantly differ between the two groups. Low prognostic index after NACRT and the absence of postoperative adjuvant chemotherapy may be adverse prognostic indicators for elderly patients undergoing NACRT for R- and BR-PDAC. Conclusions: Despite a higher incidence of postoperative complications, NACRT followed by PD can be safely performed in elderly patients, resulting in a prognosis similar to that in non-elderly patients.
- 21 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1216
Open AccessShort- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable Pancreatic Cancer: A Retrospective Study
Background: The efficacy of neoadjuvant chemoradiotherapy (NACRT) followed by pancreatoduodenectomy (PD) in elderly patients with pancreatic ductal adenocarcinoma (PDAC) remains unclear. Methods: This retrospective analysis of prospectively collected data examined the effect of NACRT followed by PD in elderly patients with PDAC. A total of 112 patients with resectable (R-) and borderline resectable (BR-) PDAC, who were planned for PD and received NACRT between 2009 and 2022, were assessed. Changes induced by NACRT, surgical outcomes, nutritional status, renal and endocrine functions, and prognosis were compared between elderly (≥75 years, n = 43) and non-elderly (n = 69) patients over two years following PD. Results: Completion and adverse event rates during NACRT, nutritional status, renal function, endocrine function over two years postoperatively, and prognosis did not significantly differ between the two groups. Low prognostic index after NACRT and the absence of postoperative adjuvant chemotherapy may be adverse prognostic indicators for elderly patients undergoing NACRT for R- and BR-PDAC. Conclusions: Despite a higher incidence of postoperative complications, NACRT followed by PD can be safely performed in elderly patients, resulting in a prognosis similar to that in non-elderly patients.
- 16 February 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (3) , 431-436
Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study
- 16 February 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (3) , 431-436
Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study